CML Ponatinib vs Bosutinib: What is Next for Research? #ASH19 @TakedaOncology
Shouryadeep Srivastava, MBBS, PhD of @TakedaOncology discusses CML patients prescribed ponatinib vs bosutinib: what is next for research?
Related Articles
Sotorasib / Lumakras + Panitumumab / Vectibix CodeBreaK 300 Shows Promise in KRAS G12C-Mutated Colorectal Cancer
Uncover the groundbreaking insights from the CodeBreaK 300 study on treating chemorefractory KRAS G12C-mutated mCRC.
FDA Approves Opdivo / Nivolumab Plus Yervoy / Ipilimumab for MSI-H/dMMR Colorectal Cancer: A Precision Oncology Milestone
Get informed about Nivolumab MSI-H Colorectal and its FDA approval. Detailed insights from the CHECKMATE-8HW trial await.
Oncology Conferences 2025-2027: Full List & Details
Prepare for Oncology Conferences 2025 to 2027. Join leading meetings such as ASCO and SABCS for the latest in cancer research.
[2025] Lung & Genitourinary Cancer Updates – Medical Oncology Association of Southern California
Empowering Oncology Professionals with Knowledge, Insights, and Innovation. Medicus Networks, Inc. 45121 Morgan Heights Rd, Temecula, CA 92592 All Rights
Cancer Warrior T-Shirt – OncologyTube – Unisex
Rock the Cancer Warrior T-Shirt! Bold, comfy, and perfect for researchers, nurses, oncologists, and patients. Available in 10 colors—proceeds support cancer awareness. Wear your strength!…
Steve Jobs Death, in 2025 could oncologist save him from pancreatic cancer?
Reflecting on Steve Jobs death, we examine his cancer journey and the evolution of treatments. What if he had today’s options?
Enfortumab Vedotin Plus Pembrolizumab vs. Chemotherapy for Untreated la/mUC: EV-302 Study Update
Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of Londonon February 17, 2025 At the 2025 ASCO Genitourinary Cancers…
Encorafenib + cetuximab (EC) BREAKWATER Study Reveals Breakthrough in Treating BRAF V600E-Mutant Metastatic Colorectal Cancer
Exciting findings from the BREAKWATER study: encorafenib and cetuximab combination therapy improves treatment outcomes for patients with BRAF V600E-mutant metastatic colorectal cancer.
Nivolumab: Does the Extended CheckMate-274 Results Prove It’s the Ultimate for MIBC? ASCO GU 2025
The Nivolumab CheckMate-274 trial reveals promising data on overall survival in muscle-invasive bladder cancer.
FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care?
The FDA approves Adcetris in a new therapy for adults with relapsed Large B-cell Lymphoma, improving overall survival rates.